* World's second listed IVF company
* Many health related companies listing
* Asaleo, Healthscope listings to come
(Adds detail on IPO market, Monash rival listing)
By Byron Kaye and Thuy Ong
SYDNEY, June 26 Shares in Australian in vitro
fertilisation company Monash IVF Group Ltd rose 6.5
percent on debut on Thursday after its private equity owner
raised A$316 million ($297 million) in its initial public
Shares in the country's second-biggest IVF company opened at
A$1.96, compared with its A$1.85 issue price and were trading at
A$1.92 at 0233 GMT, up 3.6 percent, while the broader market was
up 0.8 percent.
Private equity firms are rushing to list Australian
businesses as the share market trades near record levels and a
spate of large IPOs perform well. The country is headed for its
biggest year of new listings in almost a quarter
Many new listings are from health-related companies as
vendors hope to benefit from growing demand amid an ageing
population and a health system - including IVF - heavily
subsidised by the state.
"It follows the success of Virtus and the fact that
investors like this space," said Ric Spooner, market strategist
at CMC, referring to Monash's larger rival Virtus Health
which listed a year earlier.
Shares in Virtus, the world's first listed IVF company, were
trading up 1 percent at A$8.68, some 53 percent over their issue
On Friday, Pacific Equity Partners will list hygiene
products company Asaleo Care Ltd in the country's
second-largest listing of the year so far, having raised A$656
million in shares.
Then on Monday TPG Capital Management LP and
Carlyle Group LP are expected to lodge a prospectus with
the securities authorities to list hospital company Healthscope
in a share offer worth up to A$4 billion.
Demand for the Monash IVF IPO was so strong that Australian
private equity firm Ironbridge increased the size of the sale to
74 percent earlier this month.
($1 = 1.0639 Australian Dollars)
(Additional reporting by Lincoln Feast; Editing by Stephen